Ovarian Cancer

If approved, the combination of avutometinib with defactinib could be the first FDA-approved treatment option for low-grade serous ovarian cancer.

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Currently, VLS-1488 is being evaluated in a phase 1/2 trial (NCT05902988) in various advanced tumors, including high-grade serous ovarian cancer (HGSOC).

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.

Antibody drug conjugate TUB-040 demonstrated superior biophysical properties for treating platinum-resistant ovarian cancer.

The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.

The designation is for all patients with low-grade serous ovarian cancer, regardless of their KRAS status and after 1 or more prior lines of therapy.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

The CDK12/13 inhibitor will be tested for efficacy and safety in patients with advanced solid tumors, such as breast, ovarian, and Ewing Sarcoma.

Investigators must find a different combination or treatment regimen using a dual blockade of the PARP and PI3K/AKT/mTOR pathway.

After carboplatin joined the growing list of drug shortages, staff pharmacists acted to minimize the impact on patients.

The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.

There are currently no HER2-directed therapies for many HER2-expressing solid tumors that are refractory.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

The novel antibody-drug conjugate is the first to demonstrate overall survival benefits in patients who were already treated with therapy.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.